{
  "id": 14357282,
  "title": "Ocular Therapeutix CLO Todd Anderman sells $87,363 in company stock",
  "url": "https://urgent.news/2026/10/14/ocular-therapeutix-clo-todd-anderman-sells-87-363-in-company-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-14T03:16:19.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/ocular-therapeutix-clo-todd-anderman-sells-87363-in-company-stock-93CH-4947932"
  },
  "original_language": "en",
  "account": "On October 8, 2026, Todd Anderman, Chief Legal Officer of Ocular Therapeutix, Inc. (NASDAQ:OCUL), executed a sale of 11,984 shares of the company's common stock. The total value of these transactions amounted to $87,363, with individual shares traded between $7.10 and $7.45, resulting in an average sale price of $7.29 per share. Anderman initiated this automatic sale on October 7, 2024, specifically to meet tax withholding requirements for the vesting of restricted stock units on the same date. The company's filing indicates that these transactions were not a discretionary trade but rather a necessary action to fulfill legal obligations. Post-sell, Anderman remains the owner of 140,484 shares of Ocular Therapeutix common stock. The stock price decline of 40% for OCUL year-to-date, currently trading at $7.24, presents an undervalued opportunity according to InvestingPro analysis, which suggests potential upside. Despite the share sale, the company recently achieved a significant milestone by passing a Pre-NDAA meeting with the FDA for its drug Axpaxli, aimed at treating wet age-related macular degeneration (wAMD), with plans to submit the New Drug Application (NDA) in the fourth quarter of 2026. Market analysts have responded positively, with UBS recommending a buy rating, highlighting Axpaxli's potential as a long-acting retinal therapy with substantial market potential. RBC Capital and H.C. Wainwright have also maintained buy ratings, emphasizing Ocular Therapeutix's strong position in the competitive wAMD market, currently dominated by Regeneron and Roche. The company's strategic advancements and analyst confidence are further underscored by recent positive developments, including a favorable shift in sentiment following a Phase 3 trial failure for EyePoint Pharmaceuticals' DURAVYU treatment.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "PTC Therapeutics CLO Mark Boulding sells $12,337 in stock",
        "url": "https://urgent.news/2026/10/14/ptc-therapeutics-clo-mark-boulding-sells-12-337-in-stock",
        "published": "2026-10-14T02:31:15.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}